TY  - JOUR
A1  - van Oorschot, Birgitt
A1  - Beckmann, Gabriele
A1  - Schulze, Wolfgang
A1  - Rades, Dirk
A1  - Feyer, Petra
T1  - Radiotherapeutic options for symptom control in breast cancer
JF  - Breast Care
N2  - The majority of breast cancer patients will require radiation therapy at some time during the course of their disease. An estimated 30–50% of all radiation treatments are of palliative nature, either to alleviate symptoms or prophylactic to prevent deterioration of quality of life due to locally progressive disease. Radiotherapy is a locally effective tool, and typically causes no systemic and mostly mild acute side effects. The following article provides an overview of options and decision-making in palliative radiotherapy for symptom control.
N2  - Die Mehrzahl der Patientinnen mit Brustkrebs erhält im Krankheitsverlauf einmalig oder mehrfach eine lokale Strahlentherapie, 30–50% der Behandlungen erfolgen unter palliativer Zielsetzung, entweder zur Linderung belastender Symptome oder palliativ-präventiv zur Sicherung der Lebensqualität durch die Vermeidung lokaler Komplikationen oder eines lokalen, zeitbegrenzten Tumorprogresses. Strahlentherapie ist ein lokal wirksames Verfahren mit zumeist nur leichten Nebenwirkungen. Der vorliegende Artikel gibt einen Überblick über die Möglichkeiten der palliativen Strahlentherapie zur Symptomlinderung und über die medizinische Entscheidungsfindung.
KW  - radiotherapy
KW  - breast cancer
KW  - symptom control
KW  - palliative care
KW  - Strahlentherapie
KW  - Mammakarzinom
KW  - Symptomlinderung
KW  - Palliativmedizin
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-199105
SN  - 1661-3791
SN  - 1661-3805
N1  - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
VL  - 6
IS  - 1
ER  - 
TY  - JOUR
A1  - van Oorschot, Birgitt
A1  - Rades, Dirk
A1  - Lordick, Florian
T1  - Connections Are Clearly More Complex
JF  - Deutsches Ärzteblatt international
N2  - No abstract available.
KW  - palliative medicine
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128837
VL  - 110
IS  - 44
ER  - 
TY  - JOUR
A1  - Bolm, Louisa
A1  - Zemskov, Sergii
A1  - Zeller, Maria
A1  - Baba, Taisuke
A1  - Roldan, Jorge
A1  - Harrison, Jon M.
A1  - Petruch, Natalie
A1  - Sato, Hiroki
A1  - Petrova, Ekaterina
A1  - Lapshyn, Hryhoriy
A1  - Braun, Ruediger
A1  - Honselmann, Kim C.
A1  - Hummel, Richard
A1  - Dronov, Oleksii
A1  - Kirichenko, Alexander V.
A1  - Klinkhammer-Schalke, Monika
A1  - Kleihues-van Tol, Kees
A1  - Zeissig, Sylke R.
A1  - Rades, Dirk
A1  - Keck, Tobias
A1  - Fernandez-del Castillo, Carlos
A1  - Wellner, Ulrich F.
A1  - Wegner, Rodney E.
T1  - Concepts and outcomes of perioperative therapy in stage IA-III pancreatic cancer — a cross-validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
JF  - Cancers
N2  - (1) Background: The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers — Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2) Methods: Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3) Results: 1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4) Conclusion: The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
KW  - pancreatic cancer
KW  - perioperative therapy
KW  - neoadjuvant therapy
KW  - pancreatic surgery
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262174
SN  - 2072-6694
VL  - 14
IS  - 4
ER  -